Ask AI
ProCE Banner Activity

Integrating SGLT2 Inhibitors Across the Spectrum of Heart Failure to Improve Hyperkalemia

Clinical Thought

Read my thoughts on the importance of integrating SGLT2 inhibitors across the heart failure spectrum.

Released: November 09, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Financial Disclosures

Primary Author

Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP

The Mary and Gordon Cain Chair in Cardiology and Professor of Medicine
Senior Dean of Faculty, Baylor College of Medicine
Director, Winters Center for Heart Failure Research
Baylor College of Medicine 
Houston, Texas

Biykem Bozkurt, MD, PhD, FHFSA: consultant/advisor/speaker: Abbott, Abiomed, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardurion, Cyotkinetics, Daiichi Sankyo, Johnson & Johnson, Lantheus, Liva, Merck, Nova, Regeneron, Renovacor, Respicardia/Zoll, Roche, Sanofi-Aventis, Vifor.